BioSpace News Archive

Modular Medical, Inc., a medical device company focused on next generation insulin delivery technologies to widen the accessibility of insulin pumps to a greater share of people with type 1 and type 2 diabetes, announced that it has entered into definitive agreements for a private placement of $6.6 million of convertible promissory notes.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced its cash position as of March 31, 2021 and revenues for the first three months of 2021.

EyeGate Pharmaceuticals, Inc., a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, reported its financial results for the quarter ended March 31, 2021 and provided an update on recent corporate and operational activities.

PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash.

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported data from multiple digital presentations during the ongoing 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting as well as first quarter 2021 financial results

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference as follows:

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced that the Journal of Clinical Oncology has published a manuscript of clinical data for Cohort 2 in the C-144-01 study of lifileucel TIL therapy in metastatic melanoma.

Predictive Oncology Inc. (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended March 31, 2021 and provided an update on business activities.

The new intravascular technology, called High Frequency Optical Coherence Tomography, was successfully performed on a patient with critical coronary artery disease

Extendicare Inc. reported results for the three months ended March 31, 2021. Results are presented in Canadian dollars unless otherwise noted.